LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2015 fiscal year ended February 28, 2015, with the U.S. Securities and Exchange Commission on Tuesday, April 14, 2015. Dr. Ted Grasela, president, and Walt Woltosz, chairman and CEO, will host a conference call to discuss the Company’s performance on April 14, 2015, at 1:15 p.m. PDT / 4:15 p.m. EDT.
The conference call will be webcast live and may be joined by registering at https://attendee.gotowebinar.com/register/6758144187651868418. Upon registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (415) 655-0059, and enter access code 359-935-318.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus recently acquired Cognigen Corporation adding top quality modeling and simulations using clinical trial data to our offerings. The acquisition more than doubled our staff and added significantly to revenues. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New York. For more information, visit our Web site at www.simulations-plus.com.